Royal Philips (NYSE:PHG) announced the debut of its IntelliSpace Cognition cognitive assessment platform that uses artificial intelligence to aid healthcare professionals in assessing cognitive impairment.
The Amsterdam-based company’s IntelliSpace Cognition system is designed to automate and enhance neuropsychological tests, providing access to detailed information about a patient’s cognition while offering quantitative longitudinal data to aid in assessing disease progression and treatment efficacy. It will initially only be commercially available in the U.S.
Philips said study results showed interest in new solutions for addressing issues surrounding cognitive assessment, with 92% of neurologists indicating that the IntelliSpace Cognition concept was appealing for use within their practices. The company said a study revealed that 80% of neurologists said they would feel confident using the IntelliSpace Cognition platform.
The workflow of the IntelliSpace Cognition system includes various tests on a tablet under minimal supervision. The results are relayed to the system’s cloud-based computing platform, which applies advanced algorithms to provide results for the clinician.
“There is a real need for quantitative measures to assess the cognitive impairment of people with neurological disease,” DENT Neurologic Institute CEO Dr. Joseph Fritz said in a news release. “Computerized tools and intelligent algorithms offer new opportunities in this area to improve care. The depth of information now available and the efficiency with which we can perform assessments can be very helpful for providing feedback to patients and families sooner and developing treatment plans more quickly.”
“While dealing with the rising tide of neurological disease remains a great challenge, our solution will facilitate robust and reliable cognitive assessment with greater efficiency and scale than traditional methods,” added Philips chief innovation & strategy officer Jeroen Tas. “Combining this with imaging-based diagnostics we aim to offer care providers more meaningful insights into the health of their patients and potentially open up new possibilities for treatment in the future.”